Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.42 USD
Change Today 0.00 / 0.00%
Volume 10.8K
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

nephrogenex inc (NRX) Snapshot

Open
$4.36
Previous Close
$4.42
Day High
$4.50
Day Low
$4.29
52 Week High
12/31/14 - $17.98
52 Week Low
08/25/14 - $3.96
Market Cap
45.8M
Average Volume 10 Days
45.2K
EPS TTM
$-2.29
Shares Outstanding
10.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEPHROGENEX INC (NRX)

Related News

No related news articles were found.

nephrogenex inc (NRX) Related Businessweek News

No Related Businessweek News Found

nephrogenex inc (NRX) Details

NephroGenex, Inc., a drug development company, focuses on developing novel therapies for kidney disease. It develops Pyridorin (pyridoxamine dihydrochoride), a therapeutic agent, which is in Phase III clinical study for the treatment of diabetic nephropathy. The company also engages in studying the application of an intravenous formulation of Pyridorin to specific types of acute kidney injury in patients where pathogenic oxidative chemistries have been identified as a contributing factor to the severity of this condition. NephroGenex, Inc. was founded in 2004 and is headquartered in Raleigh, North Carolina.

11 Employees
Last Reported Date: 03/24/15
Founded in 2004

nephrogenex inc (NRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $804.1K
President and Chief Scientific Officer
Total Annual Compensation: $499.7K
Chief Financial Officer, Secretary and Treasu...
Total Annual Compensation: $432.0K
Chief Medical Officer
Total Annual Compensation: --
Vice President of Product Development & Regul...
Total Annual Compensation: $298.8K
Compensation as of Fiscal Year 2014.

nephrogenex inc (NRX) Key Developments

NephroGenex Appoints Dr. Jaikrishna Patel as Chief Medical Officer

NephroGenex, Inc. announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company's Phase 3 PIONEER program with oral Pyridorin® for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Dr. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs. In his prior roles, he also served as Vice President of Clinical Research and Medical Affairs in the Cardiovascular and Metabolism Therapeutic Area.

NephroGenex, Inc. Presents at BIO International Convention 2015, Jun-16-2015 03:15 PM

NephroGenex, Inc. Presents at BIO International Convention 2015, Jun-16-2015 03:15 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Pierre Legault, Chief Executive Officer and Director.

NephroGenex, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

NephroGenex, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. Loss from operations was $5.0 million against $1.5 million last year. The company reported net loss of $5.2 million, or $0.58 per basic and diluted share as compared to $1.7 million or $0.37 per basic and diluted share last year. The results included non-cash, stock-based compensation charges of $0.3 million in the first quarter of 2015 and $0.1 million for the first quarter of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRX:US $4.42 USD 0.00

NRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRX.
View Industry Companies
 

Industry Analysis

NRX

Industry Average

Valuation NRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPHROGENEX INC, please visit www.nephrogenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.